English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Atopic dermatitis ( AD ) is a chronic, systemic, inflammatory disease that affects the skin and is characterized by persistent itch and marked redness.  AD  is associated with an increased risk of skin infections and a reduced quality of life. Most  AD  treatment options to date were not designed to selectively target disease‐causing pathways that have been established for this indication. Topical therapies have limited efficacy in moderate‐to‐severe disease, and systemic agents such as corticosteroids and immunosuppressants present with tolerability issues. Advances in the understanding of  AD  pathobiology have made possible a new generation of more disease‐specific  AD  therapies.  AD  is characterized by the inappropriate activation of type 2 T helper (Th2) cells and type 2 innate lymphoid ( ILC 2) cells, with a predominant increase in type 2 cytokines in the skin, including interleukin ( IL )‐13 and  IL ‐4. Both cytokines are implicated in tissue inflammation and epidermal barrier dysfunction, and monoclonal antibodies targeting each of these interleukins or their receptors are in clinical development in  AD . In March 2017, dupilumab, a human anti– IL ‐4Rα antibody, became the first biologic to receive approval in the United States for the treatment of moderate‐to‐severe  AD . The anti– IL ‐13 monoclonal antibodies lebrikizumab and tralokinumab, which bind different  IL ‐13 epitopes with potentially different effects, are currently in advanced‐stage trials. Here, we briefly review the underlying pathobiology of  AD , the scientific basis for current  AD  targets, and summarize current clinical studies of these agents, including new research to develop both predictive and response biomarkers to further advance  AD  therapy in the era of precision medicine.

Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches